Has Michael Davidson received payments from drug or device companies?

Yes. Drug and device makers reported $204,170 in general payments to Michael Davidson across 400 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Davidson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Davidson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Davidson

Endocrinology, Diabetes & Metabolism · Dover, NHNPI 1225109168

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $152,082 of the $204,170 with a category attached, or 74.5%. Lilly USA, LLC accounts for 90.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $104,614 and has fallen 99.1% since, to $918 in 2022. Among endocrinology, diabetes & metabolism clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$204,170in general payments, 2019–2025

Across 400 payments — averaging $510.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$185K
Dexcom, Inc.$14K
Boehringer Ingelheim$1K
Medtronic$1K
AstraZeneca$1K
Tandem Diabetes Care, Inc.$1K
plus $72 from 2 others

$648in research payments, 2019–2025

Across 1 payment — averaging $648.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Dexcom, Inc.$648

What the payments were for

Consulting fees$11,7856%
Speaking & faculty fees$152,08274%
Travel & lodging$35,99418%
Food & beverage$4,2352%
Education$140%
Gifts$590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	361	$184,871
Dexcom, Inc.	18	$14,318
Boehringer Ingelheim	3	$1,316
Medtronic(2 entities)	4	$1,292
AstraZeneca	7	$1,184
Tandem Diabetes Care, Inc.	5	$1,117
Mannkind Corporation	1	$59
Novo Nordisk	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,170 in reported general payments places this provider in the 95th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.

See all endocrinology, diabetes & metabolism providers in New Hampshire →

Other endocrinology, diabetes & metabolism in Dover

Dylan ThomasDover$17K
Jhansi MaradanaDover$1K
Stephanie BarryDover$169
Paul TungDover$41
Matthew KamilConcord$163K
Paul LabinsonNashua$5K
Sreenija SuryadevaraLebanon$4K
Harpreet RaiLebanon$2K
Adriana Maldonado-BremManchester$800
Mini MahataStratham$558

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →